Financial Performance - Third quarter revenue from Continuing Operations was 5.3million,a1562.1 million in the same quarter last year[2] - Operating income for continuing operations was 0.1million,animprovementof1195.6 million, compared to a net loss of 13.2millionforthesameperiodlastyear[13]−Netlossfor2024was8,141, significantly improved from a loss of 47,898in2023[14]DiscontinuedOperations−Lossondiscontinuedoperationswas4.8 million for the third quarter of 2024, compared to 13.2millionforthesameperiodlastyear[7]CashandAssets−Cash,cashequivalents,marketablesecurities,andrestrictedcashtotaled12.6 million as of September 30, 2024[3] - Total current assets decreased to 27.2millionin2024from46.3 million in 2023[10] - Cash, cash equivalents, and restricted cash at the end of the period were 12,595,downfrom31,115 in 2023[14] - Accounts receivable from the sale of business was 4,478,comparedto6,111 in 2023[15] Liabilities - Total liabilities decreased to 42.5millionin2024from54.8 million in 2023[11] Cash Flow - Net cash used in operating activities totaled 27,602,adecreasefrom45,105 in the previous year[14] - Cash provided by investing activities was 16,676,comparedto47,335 in 2023[14] - Proceeds from the sale of business amounted to 13,235,downfrom17,000 in the previous year[14] Expenses - Depreciation expense for 2024 was 235,downfrom384 in 2023[14] - Non-cash stock-based compensation expense decreased to 459from1,272 in the previous year[14] Other Financial Metrics - The company reported a change in fair value of warrant liability of (107),animprovementfrom(1,478) in 2023[14] - The effect of exchange rate changes on cash was (13),comparedto(294) in the previous year[14] Guidance - The company will no longer provide financial guidance due to the announced plan to realign resources to support the left-heart access distribution business[8]
